Amgen inc.’s (AMGN) ABP 798, the biosimilar version of Rituxan, awaits the FDA decision on December 19. Rituxan is a CD20-directed cytolytic antibody that has been approved in many regions for, among other things, the treatment of adult patients alone or in combination with chemotherapy for non-Hodgkin's lymphoma, in combination with fludarabine and cyclophosphamide for chronic lymphocytic leukemia, granulomatosis with polyangiitis and microscopic polyangiitis with glucocorticoids. There are already two approved biosimilars to Rituxan – Teva/ Celltrion Healthcare’s Truxima, which was approved in November 2018, and Pfizer’s Ruxience, which was approved in July 2019.Amgen is collaborating with Allergan for the development of ABP 798.Rituxan generated global annual sales of $6.7 billion for Roche in 2019.AMGN closed Friday’s (Nov.27, 2020) trading at $224.81, up 2.04%.